Kenneth N. Rose, Benjamin J. Barlock, Nicholas A. DaSilva, Shelby L. Johnson,
Chang Liu, Hang Ma, Robert Nelson, Fatemeh Akhlaghi & Navindra P.
Seeram

ABSTRACT
Objectives: Alzheimer’s disease (AD) is a growing global health crisis exacerbated by increasing life span and an aging demographic. Convergent lines of evidence, including genome-wide association studies, strongly implicate neuroinflammation in the pathogenesis of AD. Several dietary agents, including phenolic-rich foods, show promise for the prevention and/or management of AD, which in large part, has been attributed to their anti-inflammatory effects. We previously reported
that a food-grade phenolic-enriched maple syrup extract (MSX) inhibited neuroinflammation in vitro but whether these effects are translatable in vivo remain unknown. Herein, we assessed MSX’s ability to attenuate early neuroinflammation in a transgenic mouse model of AD.
Methods: The effects of MSX on AD-related neuroinflammation was evaluated by orally administering MSX (100 and 200 mg/kg/day for 30 days) to the 3xTg-AD mouse model of AD. The expression of inflammatory markers in mouse brains were analyzed with LC-MS/MS with SWATH acquisition.
Results: 3xTg-AD mice dosed orally with MSX have decreased expression of several inflammatory proteins, including, most notably, the AD risk-associated protein ‘triggering receptor expressed on myeloid cells-2’ (TREM2), and stimulator of interferon genes TMEM173, and suppressor of cytokine signaling-6 (SOCS6). However, this decrease in inflammation did not coincide with a decrease in pathogenic amyloid generation or lipid peroxidation.
Discussion: These data demonstrate that oral administration of this maple syrup derived natural product reduces key neuroinflammatory indices of AD in the 3xTg-AD model of AD. Therefore, further studies to investigate MSX’s potential as a dietary intervention strategy for AD prevention and/or management are warranted.

https://www.tandfonline.com/doi/full/10.1080/1028415X.2019.1672009